Jorey Chernett, identified as a ten percent owner of Oncology Institute, Inc. (NASDAQ: TOI), filed a Form 4 with the Securities and Exchange Commission reporting the acquisition of 125,000 shares of common stock on March 24, 2026.
The shares were purchased at a weighted average price of $3.11, producing a total transaction value of $388,750. Individual purchase prices ranged from $3.04 to $3.15. After recording the transaction, Chernett's direct ownership in Oncology Institute stands at 10,401,929 shares.
The share purchase took place while the stock had fallen 13% over the preceding week, although year-over-year performance remains strong, with shares up 148% over the past 12 months, according to InvestingPro data. The company is trading close to its Fair Value estimate of $3.32, and analyst price targets for the stock are in a $5 to $8 range.
On the fundamentals front, Oncology Institute reported fourth-quarter 2025 results that exceeded expectations. The company recorded earnings per share of -$0.06, surpassing the forecasted -$0.09 and representing a 33.33% positive surprise relative to estimates. Reported revenue for the quarter was $141.96 million, above the anticipated $139.79 million.
There were no public announcements regarding mergers or acquisitions tied to the company in the reporting surrounding the filing. Likewise, analyst coverage has not shown recent upgrades or downgrades for Oncology Institute's stock, per the information disclosed in the filing and earnings release.
Investors monitoring Insider transactions and short-term price moves may note the timing of the purchase amid recent weakness in the share price. At the same time, reported quarterly results show revenue and EPS performance that beat expectations. The filing, valuation metrics, analyst targets and the company’s quarterly results are all relevant pieces of information for market participants assessing TOI’s current position.
Context and data points
- Transaction date: March 24, 2026
- Shares acquired: 125,000
- Weighted average price: $3.11
- Price range for purchases: $3.04 - $3.15
- Total value: $388,750
- Post-transaction direct ownership: 10,401,929 shares
- One-week share change: -13%
- One-year share change: +148%
- Fair Value: $3.32
- Analyst price targets: $5 - $8
- Q4 2025 EPS: -$0.06 (expected -$0.09) - positive surprise 33.33%
- Q4 2025 Revenue: $141.96 million (expected $139.79 million)